Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line) (TA189)
NICE does not recommend sorafenib for people with advanced hepatocellular carcinoma.
NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE applies special considerations to treatments that can extend the lives of people who are nearing the end of their life.
Sorafenib does not provide enough benefit to patients to justify its high cost, even when special considerations were applied, so NICE did not recommend it.
- TA189 Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line): guidance (web format)
This page was last updated: 30 January 2013
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- TA189 Sorafenib ar gyfer canser hepatogellog (yr iau/afu) datblygedig: deall canllawiau NICE (fformat MS Word)
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.